2023 Award-Winning AlvioLife® Formulation of Boswellia serrata Resin and Quince Fruit Extracts Clinically Shown to Lower Respiratory Tract Health and FunctionMORRISTOWN, N.J., Sept. 26, 2023 /PRNewswire/ -- PLT Health Solutions, Inc. announced that it has received an expanded license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market its ingredient AlvioLife® to support respiratory health in Canada.

2023年获奖的AlvioLife®配方Boswellia serrata树脂和木瓜果实提取物临床证明可降低呼吸道健康和功能Morristown，N.J.，2023年9月26日/PRNewswire/-PLT Health Solutions，Inc.宣布已获得加拿大卫生部天然和非处方保健产品理事会（NNHPD）的扩展许可，销售其成分AlvioLife®，以支持加拿大的呼吸系统健康。

AlvioLife is a proprietary composition of extracts of Boswellia serrata gum resin and Aegle marmelos dried fruit, designed to support respiratory health. A second clinical study conducted in 2022 confirmed efficacy in supporting lung function, aerobic exercise capacity and overall well-being..

AlvioLife是Boswellia serrata口香糖树脂和Aegle marmelos干果提取物的专有成分，旨在支持呼吸系统健康。2022年进行的第二项临床研究证实了支持肺功能，有氧运动能力和整体健康的功效。。

Continue Reading

继续阅读

In 2022, PLT announced the completion of the second double-blind placebo-controlled clinical study on AlvioLife and respiratory health. In this six-week RCT, healthy subjects who reported air pollution sensitivity took either 200 mg/day of AlvioLife or a matching placebo. Subjects taking AlvioLife experienced statistically significant improvements from baseline and compared to placebo for lung function, lung capacity and aerobic exercise capacity..

2022年，PLT宣布完成第二项关于生命和呼吸系统健康的双盲安慰剂对照临床研究。在这个为期六周的随机对照试验中，报告空气污染敏感性的健康受试者服用200毫克/天的AlvioLife或匹配的安慰剂。与安慰剂相比，服用AlvioLife的受试者在肺功能，肺容量和有氧运动能力方面经历了统计学上显着的改善。。

In Canada, the complete list of approved claims now includes:

在加拿大，批准的索赔的完整清单现在包括：

AlvioLife helps to support lower respiratory tract health

AlvioLife有助于支持下呼吸道健康

AlvioLife helps to support lower respiratory tract health that includes the bronchial tubes and the lungs' health

AlvioLife有助于支持下呼吸道健康，包括支气管和肺部健康

Supports lower respiratory system function

支持下呼吸系统功能

Clinically shown to support health lower respiratory system function

临床证明支持健康下呼吸系统功能

According to Seth Flowerman, President and CEO of PLT Health Solutions, the granting of an NHP license for AlvioLife by Health Canada is significant both because it opens the Canadian market for this unique ingredient and for what it says about the science that supports the AlvioLife. 'Respiratory health is top of mind these days, particularly with the compromised air quality we have seen throughout North America as a result of rampant wildfires,' he said.

根据PLT Health Solutions总裁兼首席执行官Seth Flowerman的说法，加拿大卫生部授予AlvioLife NHP许可证非常重要，因为它为这种独特的成分和支持AlvioLife的科学开辟了加拿大市场。'他说，呼吸系统健康是当今的重中之重，特别是由于野火猖獗，我们在北美各地看到的空气质量受损。

'The impressive anti-inflammatory effects of AlvioLife are responsible for its effectiveness in supporting respiratory health. Health Canada has a high bar for respiratory and clinically supported health claims, and we are proud of the quality of science supporting this innovative and impactful ingredient,' he added.New Clinical Study Confirms and Expands Respiratory Health Benefit MessagingIn 2022, PLT announced the completion of the second double-blind placebo-controlled clinical study on AlvioLife and respiratory health.

“AlvioLife令人印象深刻的抗炎作用是其有效支持呼吸系统健康的原因。他补充说，加拿大卫生部在呼吸和临床支持的健康声明方面有很高的门槛，我们为支持这种创新和有影响力成分的科学质量感到自豪。新的临床研究证实并扩大了呼吸系统健康益处MessagingIn 2022年，PLT宣布完成第二项关于生命和呼吸系统健康的双盲安慰剂对照临床研究。

In this six-week RCT, healthy subjects who reported air pollution sensitivity took either 200 mg/day of AlvioLife or a matching placebo. Subjects taking AlvioLife experienced statistically significant improvements from baseline and compared to placebo for lung function, lung capacity and aerobic exercise capacity.

在这个为期六周的随机对照试验中，报告空气污染敏感性的健康受试者服用200毫克/天的AlvioLife或匹配的安慰剂。服用AlvioLife的受试者与基线相比经历了统计学上显着的改善，并且与安慰剂相比，肺功能，肺容量和有氧运动能力。

In addition to these results, the study showed reductions in reported upper respiratory tract symptoms (Wisconsin Upper Respiratory Symptom Scale) and improved psychological well-being. Positive changes in immune (CD4+) and inflammatory (IL-8) biomarkers were also shown. This is the second clinical study of AlvioLife to demonstrate support for healthy respiratory activity and perceived well-being.

除了这些结果之外，研究还显示报告的上呼吸道症状（威斯康星州上呼吸道症状量表）减少，心理健康状况得到改善。还显示了免疫（CD4+）和炎性（IL-8）生物标志物的阳性变化。这是AlvioLife的第二项临床研究，旨在证明对健康呼吸活动和感知健康的支持。

The research was presented at the 2023 American Society of Nutrition meeting in Boston in Ju.

该研究在Ju波士顿的2023年美国营养学会会议上发表。